Clinical Trial Update: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is recruiting to evaluate a prototype DAA/TAA vaccine targeting MUC1 for immune interception and prevention in ductal carcinoma in situ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ductal Carcinoma in Situ

Drugs mentioned

• Prototype DAA/TAA Vaccine Targeting MUC1

Snippet

Sponsor: Finn, Olivera, PhD | Conditions: Ductal Carcinoma in Situ | Phase 1 | Status: RECRUITING